ALDA Pharmaceuticals Corp.

ALDA Pharmaceuticals Corp.

August 04, 2006 16:30 ET

ALDA Pharmaceuticals to Undertake Private Placement for Gross Proceeds of $71,500

VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - Aug. 4, 2006) - ALDA Pharmaceuticals Corp. (TSX VENTURE:APH) (the "Company") is pleased to announce that it has negotiated a non-brokered private placement of 1,430,000 units of the Company (the "Units") at a price of $0.05 per Unit for proceeds to the Company of $71,500. Each Unit consists of one common share of ALDA and one non-transferable share purchase warrant entitling the holder to acquire one additional common share of ALDA at a price of $0.10 per common share for a period of twelve (12) months from the date of the issuance of the purchase warrant.

The offering is being made on a private placement basis pursuant to registration and prospectus exemptions of applicable securities laws and is subject to acceptance by the TSX Venture Exchange. All securities issued will be subject to a four month restricted period and will bear a restrictive legend accordingly. Net proceeds from the offering will be used for working capital.

About ALDA Pharmaceuticals Corp.

ALDA has developed and markets wide spectrum, non-toxic, non-corrosive, biodegradable infection control products based on its patent-pending T(3)6® technology. Its lead product, T(3)6® Disinfectant, is acknowledged to be effective against all bacteria and viruses including Avian Flu, SARS, Norwalk Virus, HIV, Legionella and Hepatitis because of its ability to kill polio and TB.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information

  • ALDA Pharmaceuticals Corp.
    Terrance G. Owen, Ph.D., MBA
    President, CEO and Director
    ALDA Pharmaceuticals Corp.
    Aaron Genereaux
    Distribution & Sales Contact
    (604) 521-8300
    ALDA Pharmaceuticals Corp.
    Scott Young
    Investor Relations Contact
    (604) 288-7222